77412-73-8

Upstream product

• 36716-76-4 4-(p-fluorophenyl)-3-cyclohexen-1-ol 
• 29538-77-0 trans-4-hydroxycyclohexyl chloride 
• 352-13-6 4-flourophenylmagnesium bromide 
• 40503-86-4 1-(4-Fluoro-phenyl)-4-cyclohexanone 
• 13482-22-9 4-hydroxycyclohexanone 
• 40503-09-1 trans 1-(p-fluorophenyl)-1,4-cyclohexanediol 
• 36716-69-5 4-(4-fluorophenyl)-4-hydroxycyclohexanone 
• 36716-73-1 4-(p-fluorophenyl)-3-cyclohexen-1-one 
• 80912-56-7 8-(4-Fluorophenyl)-1,4-dioxaspiro[4.5]decane 
• 122770-40-5 8-(4-Fluorophenyl)-1,4-dioxaspiro[4.5]dec-7-ene 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 680596-79-6 4,4,5,5-tetramethyl-2-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1,3,2-dioxaborolane 
• 930766-10-2 1-acetyl-4-(4-fluorophenyl)cyclohexane 
• 462-06-6 fluorobenzene 

Downstream Products

• 36771-67-2 trans 4-(p-fluorophenyl)cyclohexanol methanesulfonate 
• 36826-95-6 cis 4-(p-fluorophenyl)cyclohexanol methanesulfonate 
• 36771-77-4 trans-4-(p-Fluorphenyl)-cyclohexylamin 
• 36771-79-6 cis-4-(p-Fluorphenyl)-cyclohexylamin 

Relevant academic research and scientific papers

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.

Iron-catalysed cross-coupling of halohydrins with aryl aluminium reagents: A protecting-group-free strategy attaining remarkable rate enhancement and diastereoinduction

Non-protected halohydrins are cross-coupled with aryl aluminium reagents to produce aryl alkanols in the presence of the iron-bisphosphine catalysts. Remarkable reaction rate enhancement and diastereoinduction are realized by the in situ generated aluminium alkoxides, offering a new method for the reactivity and selectivity control of the iron-catalysed cross-coupling reaction.

LIQUID-CRYSTALLINE COMPOUNDS OF THE ALICYCLIC SERIES III. SYNTHESIS AND ISOMORPHISM OF ETHERS AND ESTERS CONTAINING THE PHENYLCYCLOHEXANE FRAGMENT

A series of ethers and esters exhibiting mesomorphous characteristics were obtained from para-X-substituted trans-4-phenylcyclohexanols, trans-4-phenylcyclohexanecarboxylic acids (X = H, F, I, NO2, NH2, CN) and trans-1-hydroxymethyl-4-(p-cyanophenyl)cyclohexane.

4'-Fluoro-4-{[4-(phenyl)cyclohexyl]amino}butyrophenones and the salts thereof

This invention relates to novel 4-phenylcyclohexylamines embraced by the formula SPC1 Wherein ? is a generic expression denoting cis and trans stereoconfiguration and mixtures thereof; R is selected from the group consisting of alkyl of from one through four carbon atoms, fluorine, chlorine, bromine, trifluoromethyl, nitro and alkoxy of from one through four carbon atoms; R' and R1 are selected from the group consisting of hydrogen and alkyl of from one through four carbon atoms; R2 is selected from the group consisting of hydrogen, alkyl of from one through four carbon atoms, alkanoyl of from one through three carbon atoms, alkylsulfonyl of from one through three carbon atoms, arylsulfonyl of from six through ten carbon atoms, alkylcarbamoyl wherein alkyl is from one through four carbon atoms, alkoxycarbonyl wherein alkyl is from one through four carbon atoms, ring monosubstituted aroylalkyl wherein the substituents have the same meaning as R, above, aryl is from six through ten carbon atoms and alkyl is from one through six carbon atoms and bis (ring monosubstituted) arylalkyl wherein the substituents have the same meaning as R, above, aryl is from six through ten carbon atoms and alkyl is from one through six carbon atoms; R1 and R2 when taken together with --N is a saturated heterocyclic amino radical selected from the group consisting of unsubstituted and monosubstituted pyrrolidino, piperidino, hexamethylenimino, morpholino and piperazino; and an acid addition salt thereof. It also relates to intermediates and processes for the preparation of the aforesaid novel compounds (1) and novel derivatives thereof. The systemic administration to humans and animals of the novel compounds (1) depresses their central nervous systems.